Form 4: Century Therapeutics' Chief Scientific Officer Receives Stock Options and Restricted Stock Units

Chad Cowan, Chief Scientific Officer of Century Therapeutics, Inc., reports the acquisition of stock options and restricted stock units.

Summary

• Chad Cowan, the Chief Scientific Officer of Century Therapeutics, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On October 1, 2024, Cowan was granted 74,376 restricted stock units (RSUs), each representing a contingent right to receive one share of Century Therapeutics, Inc.'s common stock.
• These RSUs vest 25% on October 1, 2025, and the remaining 75% vest quarterly over the following three years, contingent upon Cowan's continued service.
• Cowan also acquired a stock option to purchase 446,250 shares of common stock at an exercise price of $1.65 per share.
• This option vests 25% on October 1, 2025, with the remaining 75% vesting in 36 equal monthly installments, also subject to continued service.
• Cowan also indirectly owns 10,697 shares of common stock through the Cowan Investment Nominee Trust.
• Following these transactions, Cowan directly owns 210,806 shares of common stock and 446,250 stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of equity compensation is a standard practice and generally viewed favorably as it aligns management's interests with shareholders.

Positives

• The grant of RSUs and stock options to the Chief Scientific Officer aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment and performance from the executive.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the RSUs and stock options.

Industry Context

This type of equity compensation is common in the biotechnology industry to attract and retain key executives.

Comparison to Industry Standards

• Equity grants are a standard component of compensation packages for executives in publicly traded biotechnology companies.
• Companies like Amgen, Gilead, and Biogen also use stock options and RSUs to incentivize their leadership teams.
• The vesting schedules described are typical for such grants, aligning executive compensation with long-term company performance.

Stakeholder Impact

• Shareholders may view the equity grants positively as they incentivize management to increase shareholder value.
• Employees may see the grants as a sign of the company's commitment to its leadership.

Key Dates